HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Feb. 14, 2019 (Pharmacist's Briefing) -- Achieving high serogroup B meningococcal (MenB) vaccination coverage is recommended following university-based outbreaks of meningococcal disease caused by serogroup B, according to a study published online Feb. 13 in the U.S. Centers for Disease Control and Prevention Emerging Infectious Diseases.
Heidi M. Soeters, Ph.D., M.P.H., from the CDC in Atlanta, and colleagues reviewed university-based outbreaks of meningococcal disease caused by serogroup B and vaccination responses in the years following availability of MenB vaccine.
The researchers found that during 2013 to 2018, there were 10 university-based outbreaks in seven states, which resulted in 39 cases and two deaths. The universities at which outbreaks occurred had 3,600 to 35,000 undergraduates. The number of outbreak cases varied from two to nine; duration of outbreaks varied from zero to 376 days. MenB vaccination was implemented by all 10 universities: Seven used MenB-4C and three mainly used MenB-FHbp. There was noted variation in the estimated first-dose vaccination coverage from 14 to 98 percent. In five outbreaks, additional cases occurred six to 259 days following initiation of MenB vaccination.
"Efforts are under way to better understand MenB vaccine effectiveness and duration of protection, MenB vaccine strain coverage, and current risk factors for meningococcal disease among university students," the authors write. "This information, along with lessons learned when implementing MenB vaccination campaigns, could help guide and improve responses to future outbreaks."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Read this Next
Other Trending Articles